Jack Allen
Stock Analyst at Baird
(0.81)
# 2,785
Out of 4,479 analysts
34
Total ratings
29.63%
Success rate
-25.86%
Average return
Main Sectors:
Top Industries:
16 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MREO Mereo BioPharma Group | Initiates: Outperform | $8 | $3.45 | +131.88% | 1 | Jun 13, 2024 | |
| TIL Instil Bio | Maintains: Outperform | $54 → $32 | $10.04 | +218.73% | 7 | May 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $46 → $52 | $53.12 | -2.10% | 2 | May 9, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $63 → $77 | $53.25 | +44.60% | 4 | Feb 29, 2024 | |
| BLUE bluebird bio | Maintains: Outperform | $10 → $7 | $0.92 | +658.31% | 2 | Dec 12, 2023 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $84 | $34.80 | +141.38% | 1 | Oct 31, 2023 | |
| TSHA Taysha Gene Therapies | Maintains: Outperform | $6 → $8 | $2.16 | +270.37% | 4 | Aug 15, 2023 | |
| CARM Carisma Therapeutics | Reiterates: Outperform | $10 | $1.44 | +594.44% | 2 | Jun 28, 2023 | |
| VOR Vor Biopharma | Maintains: Outperform | $38 → $22 | $0.91 | +2,307.00% | 2 | Mar 24, 2023 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $58 → $42 | $22.15 | +89.62% | 1 | Feb 24, 2023 | |
| ALLO Allogene Therapeutics | Upgrades: Outperform | $12 | $2.16 | +455.56% | 2 | Jan 6, 2023 | |
| LCTX Lineage Cell Therapeutics | Initiates: Outperform | $5 | $0.93 | +436.42% | 1 | Nov 2, 2022 | |
| FATE Fate Therapeutics | Initiates: Neutral | $28 | $3.22 | +769.57% | 1 | Jun 3, 2022 | |
| CLLS Cellectis | Upgrades: Outperform | n/a | $1.89 | - | 2 | May 18, 2022 | |
| INKT MiNK Therapeutics | Initiates: Outperform | n/a | $0.89 | - | 1 | Nov 9, 2021 | |
| VYGR Voyager Therapeutics | Upgrades: Outperform | n/a | $7.59 | - | 1 | Oct 7, 2021 |
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $3.45
Upside: +131.88%
Instil Bio
May 13, 2024
Maintains: Outperform
Price Target: $54 → $32
Current: $10.04
Upside: +218.73%
CRISPR Therapeutics AG
May 9, 2024
Maintains: Neutral
Price Target: $46 → $52
Current: $53.12
Upside: -2.10%
Arcellx
Feb 29, 2024
Maintains: Outperform
Price Target: $63 → $77
Current: $53.25
Upside: +44.60%
bluebird bio
Dec 12, 2023
Maintains: Outperform
Price Target: $10 → $7
Current: $0.92
Upside: +658.31%
Immunocore Holdings
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $34.80
Upside: +141.38%
Taysha Gene Therapies
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $8
Current: $2.16
Upside: +270.37%
Carisma Therapeutics
Jun 28, 2023
Reiterates: Outperform
Price Target: $10
Current: $1.44
Upside: +594.44%
Vor Biopharma
Mar 24, 2023
Maintains: Outperform
Price Target: $38 → $22
Current: $0.91
Upside: +2,307.00%
Intellia Therapeutics
Feb 24, 2023
Maintains: Neutral
Price Target: $58 → $42
Current: $22.15
Upside: +89.62%
Allogene Therapeutics
Jan 6, 2023
Upgrades: Outperform
Price Target: $12
Current: $2.16
Upside: +455.56%
Lineage Cell Therapeutics
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $0.93
Upside: +436.42%
Fate Therapeutics
Jun 3, 2022
Initiates: Neutral
Price Target: $28
Current: $3.22
Upside: +769.57%
Cellectis
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $1.89
Upside: -
MiNK Therapeutics
Nov 9, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.89
Upside: -
Voyager Therapeutics
Oct 7, 2021
Upgrades: Outperform
Price Target: n/a
Current: $7.59
Upside: -